Immunotherapy for hormone receptor-positive HER2-negative breast cancer

被引：0

作者：

Cardoso, Fatima ^{[1
]}

Hirshfield, Kim M. ^{[2
]}

Kraynyak, Kimberly A. ^{[2
]}

Tryfonidis, Konstantinos ^{[2
]}

Bardia, Aditya ^{[3
]}

机构：

[1] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal

[2] Merck & Co Inc, Rahway, NJ USA

[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA USA

来源：

NPJ BREAST CANCER | 2024年 / 10卷 / 01期

关键词：

PEMBROLIZUMAB PLUS CHEMOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; ADJUVANT ENDOCRINE THERAPY; OPEN-LABEL; HIGH-RISK; NEOADJUVANT CHEMOTHERAPY; LOCALLY RECURRENT; NIVOLUMAB NIVO; TRIAL; PALBOCICLIB;

D O I：

10.1038/s41523-024-00704-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Additional therapies are needed to improve outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.

引用

页数：15

共 50 条

[1] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Cantini, Luca
Trapani, Dario
Guidi, Lorenzo
Bielo, Luca Boscolo
Scafetta, Roberta
Koziej, Marcin
Vidal, Laura
Saini, Kamal S.
Curigliano, Giuseppe
CANCER TREATMENT REVIEWS, 2024, 123
[2] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
K. Almstedt
S. Mendoza
M. Otto
M. J. Battista
J. Steetskamp
A. S. Heimes
S. Krajnak
A. Poplawski
A. Gerhold-Ay
A. Hasenburg
C. Denkert
M. Schmidt
Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
[3] Molecular classification of hormone receptor-positive HER2-negative breast cancer
Jin, Xi
Zhou, Yi-Fan
Ma, Ding
Zhao, Shen
Lin, Cai-Jin
Xiao, Yi
Fu, Tong
Liu, Cheng-Lin
Chen, Yi-Yu
Xiao, Wen-Xuan
Liu, Ya-Qing
Chen, Qing-Wang
Yu, Ying
Shi, Le-Ming
Shi, Jin-Xiu
Huang, Wei
Robertson, John F. R.
Jiang, Yi-Zhou
Shao, Zhi-Ming
NATURE GENETICS, 2023, 55 (10) : 1696 - +
[4] Management of hormone receptor-positive, HER2-negative early breast cancer
Walsh, Elaine M.
Smith, Karen L.
Stearns, Vered
SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
[5] Molecular classification of hormone receptor-positive HER2-negative breast cancer
Xi Jin
Yi-Fan Zhou
Ding Ma
Shen Zhao
Cai-Jin Lin
Yi Xiao
Tong Fu
Cheng-Lin Liu
Yi-Yu Chen
Wen-Xuan Xiao
Ya-Qing Liu
Qing-Wang Chen
Ying Yu
Le-Ming Shi
Jin-Xiu Shi
Wei Huang
John F. R. Robertson
Yi-Zhou Jiang
Zhi-Ming Shao
Nature Genetics, 2023, 55 : 1696 - 1708
[6] EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
Almstedt, K.
Mendoza, S.
Otto, M.
Battista, M. J.
Steetskamp, J.
Heimes, A. S.
Krajnak, S.
Poplawski, A.
Gerhold-Ay, A.
Hasenburg, A.
Denkert, C.
Schmidt, M.
BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 137 - 146
[7] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
Matutino, A.
Joy, A. A.
Brezden-Masley, C.
Chia, S.
Verma, S.
CURRENT ONCOLOGY, 2018, 25 : S131 - S141
[8] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
Garrigos, Laia
Camacho, Daniela
Perez-Garcia, Jose Manuel
Llombart-Cussac, Antonio
Cortes, Javier
Antonarelli, Gabriele
EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
[9] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
Lopez-Tarruella, Sara
Jerez, Yolanda
Marquez-Rodas, Ivan
Echavarria, Isabel
Martin, Miguel
FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
[10] Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Andrahennadi, Samitha
Sami, Amer
Manna, Mita
Pauls, Mehrnoosh
Ahmed, Shahid
CURRENT ONCOLOGY, 2021, 28 (03) : 1803 - 1822

← 1 2 3 4 5 →